Floatz logo

EVUZAMITIDE

Systemic Amyloidosis

University of Tennessee Graduate School of Medicineprotein_peptidePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Systemic Amyloidosis cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Margarida Magalhaes-Silverman
Phase 2B
ETOPOSIDE
Margarida Magalhaes-Silverman
Phase 2B
Inno-206
Margarida Magalhaes-Silverman
Phase 2B
Thalidomide
Margarida Magalhaes-Silverman
Phase 2B
DEXAMETHASONE
Margarida Magalhaes-Silverman
Phase 2B

View all 24 →

Same molecule, other indications

EVUZAMITIDE is also rated in:

Cardiac AmyloidosisDormant
BB
Indicative ·
69 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Transthyretin AmyloidosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →